Ignite Creation Date:
2026-03-26 @ 3:18 PM
Ignite Modification Date:
2026-03-31 @ 5:28 AM
Study NCT ID:
NCT07461493
Status:
RECRUITING
Last Update Posted:
2026-03-10
First Post:
2026-03-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Cancer Stage Shifting Initiative: Registry and Biorepository to Research and Address Health Disparities in Cancer Care
Sponsor:
National Minority Quality Forum
Organization:
Study Overview
Official Title:
The Cancer Stage Shifting Initiative: Registry and Biorepository to Research and Address Health Disparities in Cancer Care
Status:
RECRUITING
Status Verified Date:
2025-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CSSI
Brief Summary:
The goal of this observational study is to establish a patient registry and a biorepository (sample collection and storage) to investigate health disparities, access, and barriers to cancer screening and early detection technologies. The registry and biorepository will serve as a resource to support Cancer Early Detection (CED) screenings and future research focused on communities at increased risk for cancer.
The study seeks to address:
•Barriers and disparities in cancer prevention, screening, and treatment, particularly in historically underrepresented populations.
Participants will:
* Attend a minimum of five clinic visits over a five-year period for scheduled annual assessments while actively enrolled in the study.
* Complete questionnaires at each visit that collect information on their medical history, cancer history, and family cancer history.
* Allow relevant health information from their electronic health records (EHR) to be collected and reviewed.
* Provide blood, saliva, and stool samples for research purposes.
* Enter a long-term follow-up period for an additional five years.
The study seeks to address:
•Barriers and disparities in cancer prevention, screening, and treatment, particularly in historically underrepresented populations.
Participants will:
* Attend a minimum of five clinic visits over a five-year period for scheduled annual assessments while actively enrolled in the study.
* Complete questionnaires at each visit that collect information on their medical history, cancer history, and family cancer history.
* Allow relevant health information from their electronic health records (EHR) to be collected and reviewed.
* Provide blood, saliva, and stool samples for research purposes.
* Enter a long-term follow-up period for an additional five years.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: